Skip to content Skip to navigation

Why Alzheimer phase 3 trials fail and how we can improve chances for success: 30 years of clinical drug development - Lon Schneider

Stanford Neurosciences Institute, Lon Schneider
February 6, 2018 - 4:00pm to 5:00pm
Li Ka Shing Center, Room 120

Why Alzheimer phase 3 trials fail and how we can improve chances for success: 30 years of clinical drug development

Lon Schneider, MD 

Professor of Psychiatry, Neurology, and Gerontology, Keck School of Medicine, University of Southern California 

 

 Bio

Lon Schneider, MD, MS is Professor of Psychiatry, Neurology, and Gerontology at the Keck School of Medicine of the University of Southern California. He is director of the California Alzheimer’s Disease Center, the Department of Psychiatry Geriatric Studies Center and co-director of the clinical core of the University of Southern California Alzheimer’s Disease Research Center (National Institutes of Health). Dr. Schneider is principal investigator of the National Institute of Mental Health CATIE program, a multicenter effectiveness trial of atypical antipsychotics in Alzheimer’s disease, and he is internationally recognized as an Alzheimer’s disease trialist.

Event Sponsor: 
Stanford ADRC: Alzheimer's Disease Research Center
Contact Email: 
Nusha Askari <askarin@stanford.edu>